Clinical Trials Browser

Phase 2 × Completed × Carcinoma, Transitional Cell × Clear all

NCT05226117 2026-03-27

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Phase 2 Completed

Carcinoma, Transitional Cell

NCT01616875 2026-03-06

Bristol Bladder Trial

Phase 2 Completed

28 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04553939 2026-01-02

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03914794 2025-10-03

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Phase 2 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Phase 2 Completed

263 enrolled 20 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell

NCT01261728 2025-08-08

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

Phase 2 Completed

Carcinoma, Transitional Cell

NCT02015104 2025-07-01

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Phase 2 Completed

32 enrolled 16 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01437488 2025-05-04

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

Phase 2 Completed

14 enrolled 12 charts

Carcinoma, Transitional Cell

NCT04602078 2025-04-24

AUREA

Phase 2 Completed

82 enrolled 20 charts

Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT02662309 2025-03-10

ABACUS

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03240016 2025-01-16

ABLE

Phase 2 Completed

36 enrolled 14 charts

Carcinoma, Transitional Cell

NCT03534804 2024-11-26

PemCab

Phase 2 Completed

37 enrolled 27 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03658304 2024-11-05

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

Phase 2 Completed

29 enrolled 11 charts

Carcinoma, Transitional Cell

NCT03219333 2024-08-27

EV-201

Phase 2 Completed

219 enrolled 32 charts 4 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Phase 2 Completed

47 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03557918 2024-07-03

Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Phase 2 Completed

26 enrolled 14 charts

Carcinoma, Transitional Cell

NCT02451423 2024-05-31

Neoadjuvant Atezolizumab in Localized Bladder Cancer

Phase 2 Completed

23 enrolled 14 charts

Carcinoma, Transitional Cell

NCT03511391 2024-01-23

CHEERS

Phase 2 Completed

DermatologicGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT04073602 2023-12-18

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Phase 2 Completed

Carcinoma, Transitional Cell

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT03809013 2023-11-27

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Phase 2 Completed

Carcinoma, Transitional Cell

NCT03390595 2023-10-18

INDUCOMAIN

Phase 2 Completed

Carcinoma, Transitional Cell

NCT03735680 2023-07-07

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

Phase 2 Completed

30 enrolled 20 charts

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03785925 2023-03-28

PIVOT-10

Phase 2 Completed

192 enrolled 16 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT02581982 2023-01-10

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Phase 2 Completed

27 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03464734 2022-11-30

Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

Phase 2 Completed

Carcinoma, Transitional Cell

NCT00805129 2022-11-25

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

46 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03980041 2022-11-25

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01688999 2022-10-18

Cabozantinib for Advanced Urothelial Cancer

Phase 2 Completed

69 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Urethral Neoplasms

NCT02500121 2022-09-30

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Phase 2 Completed

108 enrolled 15 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03558503 2022-09-16

OPTIMA II

Phase 2 Completed

63 enrolled 27 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01524991 2022-07-11

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Phase 2 Completed

36 enrolled 12 charts

Carcinoma, Transitional Cell

NCT01780545 2022-07-11

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Phase 2 Completed

200 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03945084 2022-05-23

Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy

Phase 2 Completed

Carcinoma, Transitional Cell

NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Phase 2 Completed

BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT03051373 2021-08-09

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Phase 2 Completed

Carcinoma, Transitional Cell

NCT01620970 2021-05-14

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Neoplasm Metastasis, Recurrence

NCT02788201 2020-11-06

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

Phase 2 Completed

8 enrolled 16 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00722553 2019-12-17

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Phase 2 Completed

30 enrolled 12 charts

Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Neoplasm Metastasis, Recurrence

NCT02665039 2019-10-08

VINGEM

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02351739 2019-09-10

KEYNOTE143

Phase 2 Completed

78 enrolled 10 charts

Carcinoma, Transitional Cell

NCT03507166 2019-08-21

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Phase 2 Completed

Carcinoma, Transitional Cell

NCT02109328 2019-04-11

Alisertib in Chemotherapy-pretreated Urothelial Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01529411 2019-04-04

MAJA

Phase 2 Completed

Carcinoma, Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT00880334 2018-09-18

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

Phase 2 Completed

149 enrolled 12 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02438865 2018-09-13

Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms

NCT02236195 2017-09-01

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Phase 2 Completed

Carcinoma, Transitional Cell, Rubinstein-Taybi Syndrome

NCT01828736 2017-02-06

CVH-CT02

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell